Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. R1 RCM Inc.
  6. News
  7. Summary
    RCM   US7493971052


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

R1 RCM Inc. Introduces R1 Entri™ Platform to Comprehensively Transform Patient Access and Experience Across Care Settings

08/09/2021 | 08:00am EDT

R1 RCM Inc. introduced R1 Entri™, an intelligent patient engagement solution, at booth #4721 at the HIMSS21 Global Health Conference & Exhibition in Las Vegas. Entri’s intuitive digital self-service capabilities empower patients to search, book, register and pay for care all in one experience, on any device. Entri was created to simplify the healthcare process and eliminate the pervasive friction that plagues today’s patient journeys and provider interactions. Powered by R1 proprietary technologies, automation and deep domain expertise, Entri enables the total transformation of the revenue cycle process, helping patient and provider interactions start strong and consistently develop into lasting relationships. Entri integrates the many revenue cycle touchpoints and disparate support systems found in ambulatory, acute and post-acute networks, allowing providers to manage patient access costs and intelligently match supply and demand. It also complements healthcare organizations’ existing technology infrastructures, helping them minimize disruption, streamline operations and simplify the healthcare experience.

© S&P Capital IQ 2021
All news about R1 RCM INC.
10/25R1 RCM : American Physician Partners Announces Revenue Cycle Partnership Extension with R1..
10/25American Physician Partners Announces Revenue Cycle Management Partnership Extension wi..
10/14INSIDER SELL : R1 Rcm
10/14R1 RCM : JPMorgan Starts R1 RCM at Overweight with $27 Price Target
10/12R1 RCM : to Release Third Quarter 2021 Results on November 2
09/30R1 RCM : Barclays Starts R1 RCM at Overweight With $28 Price Target
08/31R1 RCM : to Present at Upcoming Investor Conferences
08/12R1 RCM : Announces Appointment of Agnes Bundy Scanlan to Board of Directors (Form 8-K)
08/12R1 RCM INC. : Change in Directors or Principal Officers, Regulation FD Disclosure, Financi..
08/12R1 RCM : Announces Appointment of Agnes Bundy Scanlan to Board of Directors
More news
Analyst Recommendations on R1 RCM INC.
More recommendations
Financials (USD)
Sales 2021 1 467 M - -
Net income 2021 112 M - -
Net Debt 2021 626 M - -
P/E ratio 2021 -21,3x
Yield 2021 -
Capitalization 5 912 M 5 912 M -
EV / Sales 2021 4,46x
EV / Sales 2022 3,89x
Nbr of Employees 19 600
Free-Float 47,0%
Chart R1 RCM INC.
Duration : Period :
R1 RCM Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends R1 RCM INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 10
Last Close Price 21,20 $
Average target price 31,90 $
Spread / Average Target 50,5%
EPS Revisions
Managers and Directors
Joseph Gerard Flanagan President, Chief Executive Officer & Director
Rachel Wilson Chief Financial Officer, Treasurer & Executive VP
Jay Sreedharan Chief Technology & Digital Officer
Julia K. Davis Chief Information Officer & Executive VP
John Sparby COO, Executive VP-Operations & Delivery
Sector and Competitors